Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations

Childhood Leukemias, Second Edition

Volumn , Issue , 2006, Pages 391-413

  Kishi, Shinji ^a   Evans, William E ^b   Relling, Mary V ^b  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61449087672     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511471001.015     Document Type: Chapter

References (273)

1. Pui, C. H.&Evans, W. E. Acute lymphoblastic leukemia. NEngl J Med, 1998; 339: 605-15.
2. McLeod, H. L., Relling, M. V., Crom, W. R., et al. Disposition of antineoplastic agents in the very young child. Br J Cancer, 1992; 66: S23-29.
3. Evans, W. E. & Relling, M. V. Clinical pharmacodynamics of antineoplastic agents in humans. Clin Pharmacokinet, 1989; 16: 327-36.
4. Crom, W. R., Glynn-Barnhart, A. M., Rodman, J. H., et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet, 1987; 12: 168-213.
5. Jolivet, J., Schilsky, R. L., Bailey, B. D., et al. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest, 1982; 70: 351-60.
6. Fabre, I., Fabre, G., & Goldman, I. D. Polyglutamylation, an importantelementinmethotrexate cytotoxicityandselectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res, 1984; 44: 3190-5.
7. Chabner, B. A., Allegra, C. J., Curt, G. A., et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest, 1985; 76: 907-12.
8. Gorlick, R., Goker, E., Trippett, T., et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med, 1996; 335: 1041-8.
9. Whitehead, V. M., Rosenblatt, D. S., Vuchich, M. J., et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood, 1990; 76: 44-9.
10. Synold, T. W., Relling, M. V., Boyett, J. M., et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest, 1994; 94: 1996-2001.
11. Allegra, C. J., Hoang, K., Yeh, G. C., et al.Evidencefor direct inhibition ofdenovopurine synthesis inhumanMCF-7breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem, 1987; 262: 13 520-6.
12. Fry, D.W., Yalowich, J. C., & Goldman, I. D. Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem, 1982; 257: 1890-6.
13. Williams, F. M. & Flintoff, W. F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem, 1995; 270: 2987-92.
14. Moscow, J. A., Gong, M., He, R., et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res, 1995; 55: 3790-4.
15. Wong, S. C., Proefke, S. A., Bhushan, A., et al. Isolation ofhuman cDNAsthat restoremethotrexate sensitivityandreducedfolate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem, 1995; 270: 17 468-75.
16. Pizzorno, G., Mini, E., Coronnello, M., et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRFCEMcells aftershort-term, high-dosetreatmentwiththisdrug. Cancer Res, 1988; 48: 2149-55.
17. McCloskey, D. E., McGuire, J. J., Russell, C. A., et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem, 1991; 266: 6181-7.
18. Li, W. W., Waltham, M., Tong, W., et al. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol, 1993; 338: 635-8.
19. Rhee, M.S., Wang, Y., Nair, M.G., et al.Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res, 1993; 53: 2227-30.
20. Barredo, J. C., Synold, T.W., Laver, J., et al.Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood, 1994; 84: 564-9.
21. Galpin, A. J., Schuetz, J. D., Masson, E., et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylationandcytotoxicity. Mol Pharmacol, 1997; 52: 155-63.
22. Lenz, H. J., Danenberg, K., Schnieders, B., et al. Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. Oncol Res, 1994; 6: 329-35.
23. Rots, M. G., Pieters, R., Peters, G. J., et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood, 1999; 93: 1677-83.
24. Panetta, J. C., Yanishevski, Y., Pui, C. H., et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol, 2002; 50: 419-28.
25. Waltham, M.C., Li, W.W., Gritsman, H., et al.Gamma-glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. Mol Pharmacol, 1997; 51: 825-32.
26. Cole, P. D., Kamen, B. A., Gorlick, R., et al. Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res, 2001; 61: 4599-604.
27. Panetta, J. C., Wall, A., Pui, C. H., et al.Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res, 2002; 8: 2423-9.
28. Whitehead, V. M., Vuchich, M. J., Lauer, S. J., et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood, 1992; 80: 1316-23.
29. Goker, E., Lin, J. T., Trippett, T., et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia, 1993; 7: 1000-4.
30. Masson, E., Relling, M. V., Synold, T. W., et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest, 1996; 97: 73-80.
31. Dervieux, T., Brenner, T. L., Hon, Y. Y., et al.Denovo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002; 100: 1240-7.
32. Kamen, B. A. & Winick, N. J. High dose methotrexate therapy: insecure rationale? Biochem Pharmacol, 1988; 37: 2713-15.
33. Mahoney, D. H., Jr., Shuster, J., Nitschke, R., et al. Intermediatedose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology group phase III trial. J Clin Oncol, 1998; 16: 246-54.
34. Evans, W. E., Crom, W. R., Abromowitch, M., et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. NEngl J Med, 1986; 314: 471-7.
35. Evans, W. E., Schell, M. J., & Pui, C.-H. MTX clearance is more important for intermediate-risk ALL [letter; comment]. J Clin Oncol, 1990; 8: 1115-16.
36. Camitta, B., Mahoney, D., Leventhal, B., et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol, 1994; 12: 1383-9.
37. Niemeyer, C. M., Gelber, R. D., Tarbell, N. J., et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood, 1991; 78: 2514-19.
38. Schmiegelow, K., Schroder, H., Gustafsson, G., et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol, 1995; 13: 345-51.
39. Pearson, A. D. J., Amineddine, H. A., Yule, M., et al. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer, 1991; 64: 169-73.
40. Evans, W. E., Relling, M. V., Rodman, J. H., et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med, 1998; 338: 499-505.
41. Crom, W. R. & Evans, W. E. Methotrexate. In W. E. Evans, J. J. Schentag, & W. J. Jusko, eds., Applied Pharmacokinetics, 3rd edn. (Vancouver, Canada: Applied Therapeutics, Inc, 1992).
42. Relling, M. V., Fairclough, D., Ayers, D., et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol, 1994; 12: 1667-72.
43. Stoller, R. G., Hande, K. R., Jacobs, S. A., et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. NEngl J Med, 1977; 297: 630-4.
44. Jolivet, J., Cowan, K. H., Curt, G. A., et al.Thepharmacologyand clinical use of methotrexate. NEngl J Med, 1983;309: 1094-104.
45. Wall, A. M., Gajjar, A., Link, A., et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia, 2000; 14: 221-5.
46. Garre, M. L., Relling, M. V., Kalwinsky, D., et al. Pharmacokinetics and toxicity of methotrexate in children with Downsyndrome and acute lymphocytic leukemia. J Pediatr, 1987; 111: 606-12.
47. Peeters, M.&Poon, A. Downsyndromeand leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr, 1987; 146: 416-22.
48. Ueland, P. M., Refsum, H., &Christensen, B. Methotrexate sensitivity in Down's syndrome: a hypothesis. Cancer Chemother Pharmacol, 1990; 25: 384-6.
49. Peeters, M. A., Megarbane, A., Cattaneo, F., et al. Differences in purine metabolism in patients with Down's syndrome. J Intellect Disabil Res, 1993; 37: 491-505.
50. Chadefaux, B., Rethore, M. O., Raoul, O., et al. Cystathionine beta synthase: gene dosage effect in trisomy 21. Biochem Biophys Res Commun, 1985; 128: 40-4.
51. Lejeune, J., Peeters, M., Rethore, M. O., et al. Homocysteine and the methotrexate toxicity in trisomy 21[letter]. Cancer Chemother Pharmacol, 1991; 27: 331-2.
52. Horie, N., Aiba, H., Oguro, K., et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5_-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct, 1995; 20: 191-7.
53. Villafranca, E., Okruzhnov, Y., Dominguez, M. A., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promotermaypredict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol, 2001; 19: 1779-86.
54. Marsh, S., McKay, J. A., Cassidy, J., et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol, 2001; 19: 383-6.
55. Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J, 2001; 1: 65-70.
56. Rocha, C., Cheng, C., Liu, W., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005; 105: 4752-8.
57. Krajinovic, M., Costea, I., & Chiasson, S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet, 2002; 359: 1033-4.
58. Ulrich, C. M., Yasui, Y., Storb, R., et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001; 98: 231-4.
59. Chango, A., Emery-Fillon, N., de Courcy, G. P., et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab, 2000; 70: 310-5.
60. Laverdiere, C., Chiasson, S., Costea, I., et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 2002; 100: 3832-4.
61. Stet, E. H., De Abreu, R. A., Bokkerink, J. P., et al. Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine. Biochem Pharmacol, 1995; 49: 49-56.
62. Krynetski, E. Y., Krynetskaia, N. F., Yanishevski, Y., et al.Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol, 1995; 47: 1141-7.
63. Krynetski, E. Y., Tai, H. L., Yates, C. R., et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics, 1996; 6: 279-90.
64. Deininger, M., Szumlanski, C. L., Otterness, D. M., et al. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol, 1994; 48: 2135-8.
65. Tay, B. S., Lilley, R., McMurray, A. W., et al. Inhibition of phosphoribosyl pyrophosphate amidotransferase for Ehrlich ascites tumor cells by thiopurine nucleotides. Biochem Pharmacol, 1969; 18: 936-8.
66. Dervieux, T., Blanco, J. G., Krynetski, E. Y., et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res, 2001; 61: 5810-16.
67. Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet, 1980; 32: 651-62.
68. Jones, I. M., Moore, D. H., Thomas, C. B., et al. Factors affecting HPRT mutant frequency in T-lymphocytes of smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev, 1993; 2: 249-60.
69. Bredeson, C. N., Barnett, M. J., Horsman, D. E., et al. Therapyrelated acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. Leuk Lymphoma, 1993; 11: 141-5.
70. Tinel, M., Berson, A., Pessayre, D., et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol, 1991; 32: 729-34.
71. Klemetsdal, B., Tollefsen, E., Loennechen, T., et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther, 1992; 51: 24-31.
72. Szumlanski, C. L., Honchel, R., Scott, M. C., et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics, 1992; 2: 148-59.
73. Loon, J. A. Van & Weinshilboum, R. M. Human lymphocyte thiopurine methyltransferasepharmacogenetics:effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. J Pharmacol Exp Ther, 1987; 242: 21-6.
74. McLeod, H. L., Relling, M. V., Liu, Q., et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood, 1995; 85: 1897-902.
75. Szumlanski, C., Otterness, D., Her, C., et al. Thiopurine methyltransferase pharmacogenetics:humangene cloning and characterization of acommonpolymorphism. DNACell Biol, 1996; 15: 17-30.
76. Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad SciUS A, 1995; 92: 949-53.
77. Lee, D., Szumlanski, C., Houtman, J., et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA anda processed pseudogeneonhumanchromosome18q21.1. Drug Metab Dispos, 1995; 23: 398-405.
78. Tai, H. L., Krynetski, E. Y., Yates, C. R., et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet, 1996; 58: 694-702.
79. Yates, C. R., Krynetski, E. Y., Loennechen, T., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med, 1997; 126: 608-14.
80. Lennard, L., Loon, J. A. Van, & Weinshilboum, R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther, 1989; 46: 149-54.
81. Lennard, L., Loon, J. A. van, Lilleyman, J. S., et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther, 1987; 41: 18-25.
82. Escousse, A., Rifle, G., Sgro, C., et al. Azathioprine toxicity, 6-mercaptopurine accumulation and the "poor" 6-thiopurine methylator phenotype [letter]. Eur J Clin Pharmacol, 1995; 48: 309-10.
83. Schutz, E., Gummert, J., Mohr, F., et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet, 1993; 341: 436.
84. Lennard, L., Rees, C. A., Lilleyman, J. S., et al. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol, 1983; 16: 359-63.
85. Evans, W. E., Horner, M., Chu, Y. Q., et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a Cambridge Books Online (c) Cambridge University Press, 2009 Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations 407 thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr, 1991; 119: 985-9.
86. Lennard, L., Gibson, B. E., Nicole, T., et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child, 1993; 69: 577-9.
87. Relling, M. V., Hancock, M. L., Rivera, G. K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst, 1999; 91: 2001-8.
88. Evans, W. E., Hon, Y. Y., Bomgaars, L., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity amongpatients intolerant tomercaptopurine or azathioprine. J Clin Oncol, 2001; 19: 2293-301.
89. Thomsen, J., Schroder, H., Kristinsson, J., et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer, 1999; 86: 1080-6.
90. Relling, M.V., Rubnitz, J. E., Rivera, G.K., et al.Highincidenceof secondary brain tumours after radiotherapy and antimetabolites. Lancet, 1999; 354: 34-9.
91. Relling, M. V., Yanishevski, Y., Nemec, J., et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia, 1998; 12: 346-52.
92. Lennard, L., Thomas, S., Harrington, C. I., et al. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol, 1985; 113: 723-9.
93. Krynetskaia, N. F., Cai, X., Nitiss, J. L., et al. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J, 2000; 14: 2339-44.
94. Stanulla, M., Schaeffeler, E., Flohr, T., et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA, 2005; 293: 1485-9.
95. Lennard, L., Lilleyman, J. S., Loon, J. van, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet, 1990; 336: 225-9.
96. Relling, M. V., Hancock, M. L., Boyett, J. M., et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999; 93: 2817-23.
97. Davies, H. A., Lennard, L., & Lilleyman, J. S. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? Br Med J, 1993; 306: 1239-40.
98. Band, P. R., Holland, J. F., Bernard, J., et al. Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer, 1973; 32: 744-8.
99. Momparler, R. L. Kinetic and template studies with 1-_-Darabinofuranosylcytosine-5_-triphosphate and mammalian deoxyribonucleic and polymerase. Mol Pharmacol, 1972; 8: 362-70.
100. Kufe, D.W., Major, P.P., Egan, E. M., et al.Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem, 1980; 255: 8997-900.
101. Major, P. P., Sargent, L., Egan, E. M., et al. Correlation of thymidine-enhanced incorporation of ara-C in deoxyribonucleic acid with increased cell kill. Biochem Pharmacol, 1981; 30: 2221-4.
102. Major, P.P., Egan, E.M., Beardsley, G.P., et al. Lethality ofhuman myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A, 1981; 78: 3235-9.
103. Kessel, D., Hall, T. C., & Wodinsky, I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science, 1967; 156: 1240-1.
104. Wiley, J. S., Jones, S.P., Sawyer, W. H., et al.Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest, 1982; 69: 479-89.
105. Heinemann, V., Estey, E., Keating, M. J., et al. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol, 1989; 7: 622-8.
106. Plunkett, W., Liliemark, J. O., Adams, T. M., et al. Saturation 1-_-D-arabinofuranosylcytosine 5_-triphosphate accumulation in leukemic cells during high-dose 1-_-D-arabinofuranosylcytosine therapy. Cancer Res, 1987; 47: 3005-11.
107. Muus, P., Drenthe-Schonk, A., Haanen, C., et al. In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk Res, 1987; 11: 319-25.
108. White, J. C., Rathmell, J. P., Capizzi, R. L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemic cells. J Clin Invest, 1987; 79: 380-7.
109. Plunkett, W., Iacoboni, S., Estey, E., et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol, 1985; 12: 20-30.
110. Rustum, Y. M. & Preisler, H. D. Correlation between leukemic cell retention of 1-_-D-arabinofuranosylcytosine 5_-triphosphate and response to therapy. Cancer Res, 1979; 39: 42-9.
111. Bekassy, A. N., Liliemark, J., Garwicz, S., et al. Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. Med Pediatr Oncol, 1990; 18: 136-42.
112. Avramis, V. L., Biener, R., Krailo, M., et al.Biochemical pharmacology of high dose 1-_-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res, 1987; 47: 6786-92.
113. Boos, J., Hohenlochter, B., Schulze-Westhoff, P., et al. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Pediatr Oncol, 1996; 26: 397-404.
114. Plunkett, W., Iacoboni, S., & Keating, M. Cellular pharmacology and optimal therapeutic concentrations of 1-_-Darabinofuranosylcytosine 5_-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-_-D-arabinofuranosylcytosine. Scand J Haematol, 1986; 34: 51-9.
115. Estey, E. H., Keating, M. J., McCredie, K. B., et al. Cellular ara-CTP pharmacokinetics response and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia, 1990; 4: 95-9.
116. Bishop, J. F., Matthews, J. P., Young, G. A., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 1996; 87: 1710-17.
117. Mayer, R. J., Davis, R. B., Schiffer, C. A., et al. Intensive postremission chemotherapy in adults with acutemyeloid leukemia. NEngl J Med, 1994; 331: 896-903.
118. Kakihara, T., Fukuda, T., Tanaka, A., et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma, 1998; 31: 405-9.
119. Stammler, G., Zintl, F., Sauerbrey, A., et al.Deoxycytidinekinase mRNAexpression in childhood acute lymphoblastic leukemia. Anticancer Drugs, 1997; 8: 517-21.
120. Colly, L. P., Peters, W. G., Richel, D., et al. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol, 1987; 14: 257-61.
121. Veuger, M. J., Heemskerk, M. H., Honders, M. W., et al. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood, 2002; 99: 1373-80.
122. Veuger, M. J., Honders, M.W., Landegent, J. E., et al.High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood, 2000; 96: 1517-24.
123. Galmarini, C. M., Graham, K., Thomas, X., et al. Expression of high Km 5_-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood, 2001; 98: 1922-6.
124. Jahns-Streubel, G., Reuter, C., auf der Landwehr, U., et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colonystimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood, 1997; 90: 1968-76.
125. Yue, L., Saikawa, Y., Ota, K., et al.Afunctional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics, 2003; 13: 29-38.
126. Ho, D. H. W. & Frei, E., III. Clinical pharmacology of 1-_-Darabinofuranosyl cytosine. Clin Pharmacol, 1971; 12: 944-54.
127. Pui, C. H., Mahmoud, H.H., Rivera, G.K., et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood, 1998; 92: 411-15.
128. Rosner, F. & Lee, S. Down syndrome and acute leukemia: myeloblastic or lymphoblastic; report of forty-three cases and review of literature. Am J Med, 1972; 53: 203-18.
129. Robison, L. Down syndrome and leukemia. Leukemia, 1992; 6: 5-7.
130. Taub, J. W., Matherly, L. H., Stout, M. L., et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood, 1996; 87: 3395-403.
131. Kojima, S., Kato, K., Matsuyama, T., et al. Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome [letter; comment]. Blood, 1993; 81: 3164.
132. Ravindranath, Y., Abella, E., Krischer, J. P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments]. Blood, 1992; 80: 2210-14.
133. Taub, J.W., Huang, X., Matherly, L. H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 1999; 94: 1393-400.
134. Tsai, M. Y., Bignell, M., Schwichtenberg, K., et al. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet, 1996; 59: 1262-7.
135. Ge, Y., Jensen, T., James, S. J., et al. High frequency of the 844ins68 cystathionine-beta-synthase gene variant in Down syndrome children with acute myeloid leukemia. Leukemia, 2002; 16: 2339-41.
136. Gandhi, V., Estey, E., Keating, M. J., et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood, 1996; 87: 256-64.
137. Kornblau, S. M., Gandhi, V., Andreeff, H. M., et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia, 1996; 10: 1563-9.
138. Crews, K. R., Gandhi, V., Srivastava, D. K., et al. Interimcomparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol, 2002; 20: 4217-24.
139. Sirotnak, F. M., Chello, P. L., Dorick, D. M., et al. Specificity of systems mediating transport of adenosine, 9-_-Darabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells. Cancer Res, 1983; 43: 104-9.
140. Gandhi, V. & Plunkett, W. Modulation of arabinosylnucleoside metabolismby arabinosylnucleotides inhumanleukemia cells. Cancer Res, 1988; 48: 329-34.
141. Gandhi, V., Estey, E., Keating, M. J., et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol, 1993; 11: 116-24.
142. Gandhi, V., Nowak, B., Keating, M. B., et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood, 1989; 74: 2070-5.
143. Gandhi, V., Robertson, L. E., Keating, M. J., et al. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol, 1994; 34: 30-6.
144. Kemena, A., Gandhi, V., Shewach, D. S., et al. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol, 1992; 31: 193-9.
145. Estey, E., Plunkett, W., Gandhi, V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph, 1993; 9: 343-50.
146. Avramis, V. I., Wiersma, S., Krailo, M.D., et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res, 1998; 4: 45-52.
147. Dinndorf, P. A., Avramis, V. I., Wiersma, S., et al. Phase I/II studyof idarubicingivenwithcontinuousinfusionfludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol, 1997; 15: 2780-5.
148. Leahey, A., Kelly, K., Rorke, L. B., et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acutemyeloid leukemia (AML). J Pediatr Hematol Oncol, 1997; 19: 304-8.
149. Fleischhack, G., Hasan, C., Graf, N., et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remissioninduction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol, 1998; 102: 647-55.
150. Terasaki, T., Iga, T., Sugiyama, Y., et al. Experimental evidence of characteristic tissue distribution of adriamycin. TissueDNA concentration as a determinant. J Pharm Pharmacol, 1982; 34: 597-600.
151. Bachur, N. R.&Craddock, J. C. Daunomycin metabolism in rat tissue slides. J Pharmacol Exp Ther, 1971; 175: 331-7.
152. Huffman, D. H., Benjamin, R. S., &Bachur, N. R. Daunorubucin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther, 1972; 13: 895-905.
153. Gill, P., Favre, R., Durand, A., et al. Time dependency of adriamycin and adriamycinol kinetics. Cancer Chemother Pharmacol, 1983; 10: 120-4.
154. Dessypris, E. N., Brenner, D. E., & Hande, K. R. Toxicity of doxorubicin metabolites tohumanmarrowerythroidandmyeloid progenitors in vitro. Cancer Treat Rep, 1986; 70: 487-90.
155. Schott, B. & Robert, J. Comparative activity of anthracycline 13-dihydrometabolitesagainst ratglioblastomacells in culture [abstract]. Biochem Pharmacol, 1989; 38: 4069-74.
156. Olson, R. D., Mushlin, P. S., Brenner, D. E., et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A, 1988; 85: 3585-9.
157. Hempel, G., Flege, S., Wurthwein, G., et al. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol, 2002; 49: 133-41.
158. Galettis, P., Boutagy, J., & Ma, D. D. F. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br J Cancer, 1994; 70: 324-9.
159. Preisler, H. D., Gessner, T., Azarnia, N., et al. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol, 1984; 12: 125-30.
160. Kokenberg, E., Sonneveld, P., Sizoo, W., et al. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol, 1988; 6: 802-12.
161. Marie, J. P., Faussat-Suberville, A. M., Zhou, D., et al.Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia, 1993; 7: 825-31.
162. Steinberg, J. S., Cohen, A. J., Wasserman, A. G., et al. Acute arrhythmogenicity of doxorubicin administration. Cancer, 1987; 60: 1213-18.
163. Lenaz, L. & Page, J. A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev, 1976; 3: 111-20.
164. Ferrans, V. J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep, 1978; 62: 955-61.
165. Hoff, D. D. Von, Rozencweig, M., Layard, M., et al. Daunomycin-induced cardiotoxicity in children and adults. An overview of 110 cases. Am J Med, 1977; 62: 200-8.
166. Bristow, M. R., Billingham, M. E., Mason, J. W., et al. Clinical spectrumof anthracycline antibiotic cardiotoxicity. Cancer Treat Rep, 1978; 62: 873-9.
167. Friedman, M. A., Bozdech, M. J., Billingham, M. E., et al. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. J Am Med Assoc, 1978; 40: 1603-6.
168. Haq, M. M., Legha, S. S., Choksi, J., et al. Doxorubicininduced congestive heart failure in adults. Cancer, 1985; 56: 1361-5.
169. Schwartz, R. G., McKenzie, W. B., Alexander, J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicn therapy. Am J Med, 1987; 82: 1109-18.
170. Steinherz, L. J., Steinherz, P. G., Tan, C. T. C., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc, 1991; 266: 1672-7.
171. Lipshultz, S. E., Colan, S. D., Gelber, R. D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. NEngl J Med, 1991; 324: 808-15.
172. Yeung, S. T., Yoong, C., Spink, J., et al. Functional myocardial impairmentin children treated with anthracyclines for cancer. Lancet, 1991; 337: 816-18.
173. Larsen, R. L., Jakacki, R. I., Vetter, V. L., et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol, 1992; 70: 73-7.
174. Minow, R. A., Benjamin, R. S., &Gottlieb, J. A. Adriamycin(NSC-123127) cardiomyopathy-an overview with determination of risk factors. Cancer Chemother Rep, 1975; 6: 195-201.
175. Mosijczuk, A. D., Ruymann, F. B., Mease, A. D., et al. Anthracycline cardiomyopathy in children-report oftwocases. Cancer, 1979; 44: 1582-7.
176. Pratt, C. B., Ransom, J. L., & Evans, W. E. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep, 1978; 62: 1381-5.
177. Lipshultz, S. E., Giantris, A. L., Lipsitz, S. R., et al. Doxorubicin administrationby continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol, 2002; 20: 1677-82.
178. Daghestani, A. N., Arlin, Z. A., Leyland-Jones, B., et al. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res, 1985; 45: 1408-12.
179. Gill, P. S., Espina, B. M., Muggia, F., et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol, 1995; 13: 996-1003.
180. Uziely, B., Jeffers, S., Isacson, R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol, 1995; 13: 1777-85.
181. Wolff, A. C., Ettinger, D. S., Neuberg, D., et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol, 1995; 13: 1615-22.
182. Ochs, J., Rodman, J., Abromowitch, M., et al. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol, 1991; 9: 139-44.
183. Rivera, G. K., Hudson, M. M., Liu, Q., et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood, 1996; 88: 831-7.
184. Lowis, S. P. & Newell, D. R. Etoposide for the treatment of paediatric tumours: what is the best way to give it? Eur J Cancer, 1996; 32A: 2291-7.
185. Clark, P. I. & Slevin, M. L. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet, 1987; 12: 223-52.
186. Relling, M. V., Nemec, J., Schuetz, E. G., et al. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol, 1994; 45: 352-8.
187. Relling, M. V., Evans, R., Dass, C., et al. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther, 1992; 261: 491-6.
188. Liliemark, E. K., Liliemark, J., Pettersson, B., et al. In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. Leuk Lymphoma, 1993; 10: 323-8.
189. Relling, M. V., Mahmoud, H. H., Pui, C.-H., et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol, 1996; 14: 399-404.
190. Gaast, A. van der, Sonneveld, P., Mans, D. R. A., et al. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol, 1992; 29: 335-7.
191. Ratain, M. J., Mick, R., Schilsky, R. L., et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol, 1991; 9: 1480-6.
192. Karlsson, M. O., Port, R. E., Ratain, M. J., et al. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther, 1995; 57: 325-34.
193. Clark, P. I., Slevin, M. L., Joel, S. P., et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokineticsonefficacyandtoxicity. J Clin Oncol, 1994; 12: 1427-35.
194. Relling, M. V., McLeod, H., Bowman, L., et al. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther, 1994; 56: 503-11.
195. Stewart, C. F., Arbuck, S. G., Fleming, R. A., et al.Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther, 1991; 50: 385-93.
196. Ratain, M. J., Schilsky, R. L., Choi, K. E., et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther, 1989; 45: 226-33.
197. Sonnichsen, D. S., Ribeiro, R. C., Luo, X., et al. Pharmacokinetics and pharmacodynamics of 21 day continuous oral etoposide in pediatric solid tumor patients. Clin Pharmacol Ther, 1995; 58: 99-107.
198. Evans, W. E., Rodman, J. H., Relling, M. V., et al. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed versus relapsed acute lymphocytic leukemia. J Pharmacol Exp Ther, 1992; 260: 71-7.
199. Clark, P. I. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin Oncol, 1992; 19: 20-7.
200. Rodman, J. H., Murry, D. J., Madden, T., et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol, 1994; 12: 2390-7.
201. Edick, M. J., Gajjar, A., Mahmoud, H., et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol, 2003; 21: 1340-6.
202. McLeod, H. L., Baker, D. K., Jr., Pui, C.-H., et al. Somnolence, hypotension, andmetabolic acidosis followinghigh-doseteniposidetreatmentin childrenwithleukemia. Cancer Chemother Pharmacol, 1991; 29: 150-4.
203. Rodman, J. H., Abromowitch, M., Sinkule, J. A., et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J Clin Oncol, 1987; 5: 1007-14.
204. Davies, S. M., Robison, L. L., Buckley, J. D., et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol, 2001; 19: 1279-87.
205. Adamson, P. C., Bailey, J., Pluda, J., et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol, 1995; 13: 1238-41.
206. Adamson, P. C., Boylan, J. F., Balis, F. M., et al. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res, 1993; 53: 472-6.
207. Muindi, J. F. & Young, C. W. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Can Res, 1993; 53: 1226-9.
208. Takitani, K., Tamai, H., Morinobu, T., et al. Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. Jpn J Cancer Res, 1995; 86: 400-5.
209. Adamson, P. C., Reaman, G., Finklestein, J. Z., et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administeredonanintermittentscheduleincombinationwith interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol, 1997; 15: 3330-7.
210. Agadir, A., Cornic, M., Lefebvre, P., et al. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. J Clin Oncol, 1995; 13: 2517-23.
211. Conley, B. A., Egorin, M. J., Sridhara, R., et al. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol, 1997; 39: 291-9.
212. Jones, B., Holland, J. F., Glidewell, O., et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol, 1977; 3: 387-400.
213. Capizzi, R. L., Bertino, J. R., Skeel, R. T., et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med, 1971; 74: 893-901.
214. Ohnuma, T., Holland, J. F., Freeman, A., et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res, 1970; 30: 2297-305.
215. Schwartz, M.K., Lash, E.D., Oettgen, H.F., et al. L-Asparaginase activity in plasma and other biological fluids. Cancer, 1970; 25: 244-52.
216. Ho, D. H., Thetford, B., Carter, C. J., et al. Clinical pharmacologic studies of L-asparaginase. Clin Pharmacol Ther, 1970; 11: 408-17.
217. Asselin, B. L., Whitin, J. C., Coppola, D. J., et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol, 1993; 11: 1780-6.
218. Avramis, V. I., Sencer, S., Periclou, A. P., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 2002; 99: 1986-94.
219. Silverman, L.B., Gelber, R.D., Dalton, V. K., et al.Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, 2001; 97: 1211-18.
220. Cheung, N.-K. V., Chau, I. Y., Coccia, P. F. Antibody response to Escherichia coli L-asparaginase. Am J Pediatr Hematol Oncol, 1986; 8: 99-104.
221. Killander, D., Dohlwitz, A., Engstedt, L., et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer, 1976; 37: 220-8.
222. Woo, M. H., Hak, L. J., Storm, M. C., et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia, 1998; 12: 1527-33.
223. Abshire, T. C., Pollock, B. H., Billett, A. L., et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood, 2000; 96: 1709-15.
224. Gentili, D., Zucchetti, M., Conter, V., et al. Determination of L-asparagine in biological samples in the presence of Lasparaginase. J Chromatogr Biomed Appl, 1994; 657: 47-52.
225. Woo, M. H., Hak, L. J., Storm, M. C., et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol, 2000; 18: 1525-32.
226. Hak, L. J., Relling, M. V., Cheng, C., et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia, 2004; 18: 1072-7.
227. Woo, M. H., Hak, L. J., Storm, M. C., et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol, 1999; 17: 1568-73.
228. Ahlke, E., Nowak-Gottl, U., Schulze-Westhoff, P., et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol, 1997; 96: 675-81.
229. Schwartz, S. A., Morgenstern, B., & Capizzi, R. L. Scheduledependent synergy and antagonism between high-dose 1-_-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. Cancer Res, 1982; 42: 2191-7.
230. Jolivet, J., Cole, D. E., Holcenberg, J. S., et al. Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Cancer Res, 1985; 45: 217-20.
231. French, M., Manel, A. M., Magaud, J. P., et al. Adult acute lymphoblastic leukaemia: is cell proliferation related to other clinical and biological features? Br J Haematol, 1987; 65: 419-23.
232. Sur, P., Fernandes, D. J., Kute, T. E., et al. L-asparaginaseinduced modulation of methotrexate polyglutamylation in murine leukemia L5178Y1. Cancer Res, 1987; 47: 1313-18.
233. Amylon, M. D., Shuster, J., Pullen, J., et al. Intensive highdose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia, 1999; 13: 335-42.
234. Pui, C. H., Relling, M. V., Behm, F. G., et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia, 1995; 9: 1680-4.
235. Veerman, A. J. P., Hahlen, K., Kamps, W. A., et al. High cure rate with a moderately intensive treatment regimen in nonhigh-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol, 1996; 14: 911-18.
236. Schwartz, C. L., Thompson, E. B., Gelber, R. D., et al. Improved response with higher corticosteroid dose in childrenwithacutelymphoblasticleukemia. J Clin Oncol, 2001;19: 1040-6.
237. Ito, C., Evans, W. E., McNinch, L., et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol, 1996; 14: 2370-6.
238. Kaspers, G. J. L., Veerman, A. J. P., Pop-Snijders, C., et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol, 1996; 27: 114-21.
239. Gaynon, P. S., Trigg, M. E., Heerema, N. A., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia, 2000; 14: 2223-33.
240. Gaynon, P. S., Bostrom, B. C., Hutchinson, R. J., et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol, 2001; 19: 1916-25.
241. Jones, B., Freeman, A. I., Shuster, J. J., et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol, 1991; 19: 269-75.
242. Meikle, A. W. & Tyler, F. H. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med, 1977; 63: 200-7.
243. Hurwitz, C. A., Silverman, L. B., Schorin, M. A., et al. Substituting dexamethasone for prednisone complicates remission inductionin childrenwithacutelymphoblasticleukemia. Cancer, 2000; 88: 1964-9.
244. Lausten, G. S., Egfjord, M., & Olgaard, K. Metabolism of prednisone in kidney transplanted patients with necrosis of the femoral head. Pharmacol Toxicol, 1993; 72: 78-83.
245. Mattano, L. A., Jr., Sather, H.N., Trigg, M.E., et al.Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol, 2000; 18: 3262-72.
246. Hurley, D. M., Accili, D., Stratakis, C. A., et al. Point mutation causing a single amino acid substitution in the hormonebinding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest, 1991; 87: 680-6.
247. Weaver, J. U., Hitman, G. A., Kopelman, P. G. An association between a Bc1I restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J Mol Endocrinol, 1992; 9: 295-300.
248. Rossum, E. F. van, Koper, J. W., Huizenga, N. A., et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes, 2002; 51: 3128-34.
249. De Rijk, R. H., Schaaf, M., & de Kloet, E. R. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol, 2002; 81: 103-22.
250. Tissing, W. J., Meijerink, J. P., Noer, M. L. den, & Pieters, R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia, 2003; 17: 17-25.
251. Kishi, S., Yang, W., Morand, S., et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood, 2004; 103: 67-72.
252. Anderer, G., Schrappe, M., Brechlin, A. M., et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics, 2000; 10: 715-26.
253. Desai, Z. R., Berg, H.W. van den, Bridges, J. M., et al. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol, 1982; 8: 211-14.
254. de Graaf, S. S., Bloemhof, H., Vendrig, D. E., et al. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol, 1995; 24: 235-40.
255. Gidding, C. E., Meeuwsen-de Boer, G. J., Koopmans, P., et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol, 1999; 44: 203-9.
256. Groninger, E., Meeuwsen-De Boar, T., Koopmans, P., et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res, 2002; 52: 113-18.
257. Villikka, K., Kivisto, K.T., Maenpaa, H., et al.CytochromeP450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther, 1999; 66: 589-93.
258. Kamaluddin, M., McNally, P., Breatnach, F., et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr, 2001; 90: 1204-7.
259. Lamba, J. K., Lin, Y. S., Thummel, K., et al. Commonallelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 2002; 12: 121-32.
260. Kuehl, P., Zhang, J., Lin, Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001; 27: 383-91.
261. Hoffmeyer, S., Burk, O., Richter, O. von, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 2000; 97: 3473-8.
262. Jackson, D. V., Castle, M. C., & Bender, R. A. Biliary excretion of vincristine. Clin Pharmacol Ther, 1978; 24: 101-7.
263. Crom, W. R., de Graaf, S. S., Synold, T., et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr, 1994; 125: 642-9.
264. Woods, W. G., O'Leary, M., & Nesbit, M. E. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr, 1981; 98: 642-5.
265. Niemeyer, C. M., Hitchcock-Bryan, S., Sallan, S. E. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol, 1985; 12: 122-30.
266. Pinkel, D., Hernandez, K., Borella, L., et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer, 1971; 37: 247-56.
267. Reiter, A., Schrappe, M., Wolf-Dieter, L., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALLBFM 86. Blood, 1994; 84: 3122-33.
268. Kamen, B. A., Frenkel, E., & Colvin, O. M. Ifosfamide: should the honeymoon be over? J Clin Oncol, 1995; 13: 307-9.
269. Yule, S. M., Price, L., Pearson, A. D., et al. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res, 1997; 3: 1985-92.
270. Ayash, L. J., Wright, J. E., Tretyakov, O., et al.Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol, 1992; 10: 995-1000.
271. Huang, Z., Roy, P., &Waxman, D. J. Role ofhumanlivermicrosomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol, 2000; 59: 961-72.
272. Lang, T., Klein, K., Fischer, J., et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function inhumanliver. Pharmacogenetics, 2001; 11: 399-415.
273. Sweeney, C., McClure, G. Y., Fares, M. Y., et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1Ile105Valpolymorphism. Cancer Res, 2000; 60: 5621-4.